echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Lyon Biotech's TCR-T Therapy Receives FDA Fast Track Designation for Hepatocellular Carcinoma

    Lyon Biotech's TCR-T Therapy Receives FDA Fast Track Designation for Hepatocellular Carcinoma

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TextPharmaceutical Guanlan

    Today (December 23), Lion TCR Pte Ltd (Lion TCR Pte Ltd, hereinafter referred to as "Lion Bio") announced that its potential "first-in-class" therapy LioCyx-M004 has been granted Fast Track by the US FDA Eligibility for the treatment of hepatitis B-related hepatocellular carcinoma


    Lyon Bio is a clinical-stage biotechnology company


    LioCyx-M004 is the product with the fastest research progress in Lyon's product pipeline


    In early Phase 1 clinical studies, LioCyx-M004 has demonstrated a good safety profile and significantly improved patient survival


    Dr.


    Dr.


    According to the press release, there are 420,000 new patients with hepatitis B-related hepatocellular carcinoma each year.


    References:

    [1] Lion Bio received FDA Fast Track Designation: Application of HBV-specific TCR-T in the treatment of hepatocellular carcinoma.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.